STOCK TITAN

Precigen Inc - PGEN STOCK NEWS

Welcome to our dedicated news page for Precigen (Ticker: PGEN), a resource for investors and traders seeking the latest updates and insights on Precigen.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Precigen's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Precigen's position in the market.

Rhea-AI Summary
Precigen, Inc. (PGEN) to Present Company Overview at Stifel 2023 Healthcare Conference in New York
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.82%
Tags
conferences
-
Rhea-AI Summary
Precigen, Inc. (Nasdaq: PGEN) announces participation in upcoming investor and industry conferences.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.06%
Tags
conferences
-
Rhea-AI Summary
Precigen, Inc. announces FDA confirmation of pivotal study for PRGN-2012 in RRP and plans to reduce costs. Cash runway projected into 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.9%
Tags
Rhea-AI Summary
Precigen, Inc. announced that the ongoing Phase 1/2 study of PRGN-2012 AdenoVerse immunotherapy for recurrent respiratory papillomatosis (RRP) will serve as pivotal for filing an accelerated approval request for licensure. The FDA confirmed no additional randomized, placebo-controlled trial will be required. Enrollment and dosing in the Phase 2 portion of the study is completed. PRGN-2012 could potentially be the first therapeutic for RRP, a difficult-to-treat orphan indication. The current standard-of-care is repeated surgeries.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.9%
Tags
-
Rhea-AI Summary
Precigen, Inc. (Nasdaq: PGEN) announced the release of second quarter and first half 2023 financial results on August 9, 2023. The company will host a conference call to discuss financial results and provide a general business update. Event details can be found on Precigen's website. Precigen is a biopharmaceutical company specializing in gene and cell therapies for immuno-oncology, autoimmune disorders, and infectious diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.89%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.46%
Tags
none
-
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.97%
Tags
Precigen Inc

Nasdaq:PGEN

PGEN Rankings

PGEN Stock Data

353.46M
122.48M
11.72%
64.45%
6.79%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
US
Germantown

About PGEN

precigen, inc. discovers and develops the next generation of gene and cellular therapies in the united states. it also provides disease-modifying therapeutics; genetically engineered swine for regenerative medicine applications; proprietary methane bioconversion platform that turns natural gas into energy and chemical products; and reproductive and embryo transfer technologies. in addition, the company offers ultravector platform that incorporates advanced dna construction technologies and computational models to design and assemble genetic components into complex gene expression programs; mbil15, a gene that enhances functional characteristics of immune cells; sleeping beauty, a non-viral transposon/transposase system; attsite recombinases, which breaks and rejoins dna at specific sequences; adenoverse technology platform, a library of engineered adenovector serotypes; and l. lactis is a food-grade bacterium. additionally, it provides rheoswitch inducible gene switch that provides qua